To evaluate this idea, we ectopically expressed the wild-type and S463D mutant of TFEB in three human cancer cell lines to modulate lysosomal acidification/activation and treated the cells with EGFR inhibitors under hypoxia. The gene discussed is EGFR; the disease is cancer.